Search

Your search keyword '"Asakura, Yoshitaka"' showing total 30 results
Start Over Author "Asakura, Yoshitaka"
30 results on '"Asakura, Yoshitaka"'

4. Characterization of patients with aggressive adult T-cell leukemia–lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort

Author

Nishi, Yukiko, Fukushima, Takuya, Nomura, Shogo, Tomoyose, Takeaki, Nakachi, Sawako, Morichika, Kazuho, Tedokon, Iori, Tamaki, Keita, Shimabukuro, Natsuki, Taira, Naoya, Miyagi, Takashi, Karimata, Kaori, Ohama, Masayo, Yamanoha, Atsushi, Tamaki, Kazumitsu, Hayashi, Masaki, Arakaki, Hitoshi, Uchihara, Jun-Nosuke, Ohshiro, Kazuiku, Asakura, Yoshitaka, Kuba-Miyara, Megumi, Karube, Kennosuke, and Masuzaki, Hiroaki

Published
2016
Full Text
View/download PDF

6. Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma

Author

Tada, Kohei, Kim, Sung-Won, Asakura, Yoshitaka, Hiramoto, Nobuhiro, Yakushijin, Kimikazu, Kurosawa, Saiko, Tajima, Kinuko, Mori, Shin-ichiro, Heike, Yuji, Tanosaki, Ryuji, Maeshima, Akiko Miyagi, Taniguchi, Hirokazu, Furuta, Koh, Kagami, Yoshikazu, Matsuno, Yoshihiro, Tobinai, Kensei, Takaue, Yoichi, and Fukuda, Takahiro

Published
2012
Full Text
View/download PDF

8. Frequent inactivation of A20 in B-cell lymphomas

Author

Kato, Motohiro, Sanada, Masashi, Kato, Itaru, Sato, Yasuharu, Takita, Junko, Takeuchi, Kengo, Niwa, Akira, Chen, Yuyan, Nakazaki, Kumi, Nomoto, Junko, Asakura, Yoshitaka, Muto, Satsuki, Tamura, Azusa, Iio, Mitsuru, Akatsuka, Yoshiki, Hayashi, Yasuhide, Mori, Hiraku, Igarashi, Takashi, Kurokawa, Mineo, Chiba, Shigeru, Mori, Shigeo, Ishikawa, Yuichi, Okamoto, Koji, Tobinai, Kensei, Nakagama, Hitoshi, Nakahata, Tatsutoshi, Yoshino, Tadashi, Kobayashi, Yukio, and Ogawa, Seishi

Published
2009
Full Text
View/download PDF

9. Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma

Author

Nomoto Junko, Hiramoto Nobuhiro, Kato Motohiro, Sanada Masashi, Maeshima Akiko, Taniguchi Hirokazu, Hosoda Fumie, Asakura Yoshitaka, Munakata Wataru, Sekiguchi Naohiro, Maruyama Dai, Watanabe Takashi, Nakagama Hitoshi, Takeuchi Kengo, Tobinai Kensei, Ogawa Seishi, and Kobayashi Yukio

Subjects
FICTION analysis, Hodgkin lymphoma, TNFAIP3 gene, Homozygous deletion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The TNFAIP3 gene, which encodes a ubiquitin-modifying enzyme (A20) involved in the negative regulation of NF-κB signaling, is frequently inactivated by gene deletions/mutations in a variety of B-cell malignancies. However, the detection of this in primary Hodgkin lymphoma (HL) specimens is hampered by the scarcity of Hodgkin Reed-Sternberg (HR-S) cells even after enrichment by micro-dissection. Methods We used anti-CD30 immunofluorescence with fluorescence in-situ hybridization (FISH) to evaluate the relative number of TNFAIP3/CEP6 double-positive signals in CD30-positive cells. Results From a total of 47 primary classical Hodgkin lymphoma (cHL) specimens, 44 were evaluable. We found that the relative numbers of TNFAIP3/CD30 cells were distributed among three groups, corresponding to those having homozygous (11%), heterozygous (32%), and no (57%) deletions in TNFAIP3. This shows that TNFAIP3 deletions could be sensitively detected using our chosen methods. Conclusions Comparing the results with mutation analysis, TNFAIP3 inactivation was shown to have escaped detection in many samples with homozygous deletions. This suggests that TNFAIP3 inactivation in primary cHL specimens might be more frequent than previously reported.

Published
2012
Full Text
View/download PDF

10. RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey

Author

Kim, Sung-Won, primary, Asakura, Yoshitaka, additional, Tajima, Kinuko, additional, Iwai, Toshiki, additional, Taji, Hirofumi, additional, Chou, Takaaki, additional, Morishima, Yasuo, additional, Suzumiya, Junji, additional, Sakamaki, Hisashi, additional, Suzuki, Ritsuro, additional, and Fukuda, Takahiro, additional

Published
2019
Full Text
View/download PDF

11. Evaluation of two prognostic indices for adult T‐cell leukemia/lymphoma in the subtropical endemic area, Okinawa, Japan

Author

Tamaki, Keita, Morishima, Satoko, Nomura, Shogo, Nishi, Yukiko, Nakachi, Sawako, Kitamura, Sakiko, Uchibori, Sachie, Tomori, Shouhei, Hanashiro, Taeko, Shimabukuro, Natsuki, Tedokon, Iori, Morichika, Kazuho, Taira, Naoya, Tomoyose, Takeaki, Miyagi, Takashi, Karimata, Kaori, Ohama, Masayo, Yamanoha, Atsushi, Tamaki, Kazumitsu, Hayashi, Masaki, Uchihara, Jun-nosuke, Ohshiro, Kazuiku, Asakura, Yoshitaka, Kuba-Miyara, Megumi, Karube, Kennosuke, Fukushima, Takuya, Masuzaki, Hiroaki, Tamaki, Keita, Morishima, Satoko, Nomura, Shogo, Nishi, Yukiko, Nakachi, Sawako, Kitamura, Sakiko, Uchibori, Sachie, Tomori, Shouhei, Hanashiro, Taeko, Shimabukuro, Natsuki, Tedokon, Iori, Morichika, Kazuho, Taira, Naoya, Tomoyose, Takeaki, Miyagi, Takashi, Karimata, Kaori, Ohama, Masayo, Yamanoha, Atsushi, Tamaki, Kazumitsu, Hayashi, Masaki, Uchihara, Jun-nosuke, Ohshiro, Kazuiku, Asakura, Yoshitaka, Kuba-Miyara, Megumi, Karube, Kennosuke, Fukushima, Takuya, and Masuzaki, Hiroaki

Abstract

Aggressive adult T‐cell leukemia/lymphoma (ATL) has an extremely poor prognosis and is hyperendemic in Okinawa, Japan. This study evaluated two prognostic indices (PIs) for aggressive ATL, the ATL‐PI and Japan Clinical Oncology Group (JCOG)‐PI, in a cohort from Okinawa. The PIs were originally developed using two different Japanese cohorts that included few patients from Okinawa. The endpoint was overall survival (OS). Multivariable Cox regression analyses in the cohort of 433 patients revealed that all seven factors for calculating each PI were statistically significant prognostic predictors. Three‐year OS rates for ATL‐PI were 35.9% (low‐risk, n = 66), 10.4% (intermediate‐risk, n = 256), and 1.6% (high‐risk, n = 111), and those for JCOG‐PI were 22.4% (moderate‐risk, n = 176) and 5.3% (high‐risk, n = 257). The JCOG‐PI moderate‐risk group included both the ATL‐PI low‐ and intermediate‐risk groups. ATL‐PI more clearly identified the low‐risk patient subgroup than JCOG‐PI. To evaluate the external validity of the two PIs, we also assessed prognostic discriminability among 159 patients who loosely met the eligibility criteria of a previous clinical trial. Three‐year OS rates for ATL‐PI were 34.5% (low‐risk, n = 42), 9.2% (intermediate‐risk, n = 109), and 12.5% (high‐risk, n = 8). Those for JCOG‐PI were 22.4% (moderate‐risk, n = 95) and 7.6% (high‐risk, n = 64). The low‐risk ATL‐PI group had a better prognosis than the JCOG‐PI moderate‐risk group, suggesting that ATL‐PI would be more useful than JCOG‐PI for establishing and examining novel treatment strategies for ATL patients with a better prognosis. In addition, strongyloidiasis, previously suggested to be associated with ATL‐related deaths in Okinawa, was not a prognostic factor in this study.

Published
2018

12. High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey.

Author

Kim, Sung-Won, Asakura, Yoshitaka, Tajima, Kinuko, Iwai, Toshiki, Taji, Hirofumi, Chou, Takaaki, Morishima, Yasuo, Suzumiya, Junji, Sakamaki, Hisashi, Suzuki, Ritsuro, and Fukuda, Takahiro

Subjects
STEM cell transplantation, RELATIVE medical risk, SURVIVAL, AGE distribution, B cell lymphoma, PROGNOSIS, SEX distribution, AUTOGRAFTS, RESEARCH funding
Abstract

To investigate the use of high-dose therapy and autologous stem cell transplantation (ASCT) for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL) between 1990 and 2007, we conducted a nationwide survey using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Of the 1222 patients in the database, 576 (47%) received ASCT in first complete remission (CR1), 140 (12%) in first partial remission, 281 (23%) in sensitive relapse, 150 (12%) in resistant or sensitivity-unknown relapse, and 75 (6%) in primary refractory status. With a median follow-up of 22 months, the 2-year overall survival (OS) and progression-free survival rates were 71% and 68%, respectively. The cumulative incidences of 2-year non-relapse mortality and relapse/progression were 6% and 26%, respectively. Relapse/progression after ASCT in the rituximab era (2002-2007) was significantly lower than that in the pre-rituximab era (1990-2001; P < 0.001). Older age, male gender, poor performance status at ASCT, non-CR1 at ASCT, ASCT performed in 1990-2001, and LEED or MCEC regimen were adverse predictors of OS. Because ASCT for newly diagnosed high-risk DLBCL has not been performed recently, a registry database study to assess the impact of ASCT for relapsed or refractory DLBCL in the rituximab era is warranted. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

13. Evaluation of two prognostic indices for adult T‐cell leukemia/lymphoma in the subtropical endemic area, Okinawa, Japan

Author

Tamaki, Keita, primary, Morishima, Satoko, additional, Nomura, Shogo, additional, Nishi, Yukiko, additional, Nakachi, Sawako, additional, Kitamura, Sakiko, additional, Uchibori, Sachie, additional, Tomori, Shouhei, additional, Hanashiro, Taeko, additional, Shimabukuro, Natsuki, additional, Tedokon, Iori, additional, Morichika, Kazuho, additional, Taira, Naoya, additional, Tomoyose, Takeaki, additional, Miyagi, Takashi, additional, Karimata, Kaori, additional, Ohama, Masayo, additional, Yamanoha, Atsushi, additional, Tamaki, Kazumitsu, additional, Hayashi, Masaki, additional, Uchihara, Jun‐nosuke, additional, Ohshiro, Kazuiku, additional, Asakura, Yoshitaka, additional, Kuba‐Miyara, Megumi, additional, Karube, Kennosuke, additional, Fukushima, Takuya, additional, and Masuzaki, Hiroaki, additional

Published
2018
Full Text
View/download PDF

15. External validation of prognostic indices for aggressive adult T-cell leukemia/lymphoma (ATL-PI/JCOG-PI) in Okinawa.

Author

Tamaki, Keita, primary, Morishima, Satoko, additional, Nomura, Shogo, additional, Tomoyose, Takeaki, additional, Nakachi, Sawako, additional, Nishi, Yukiko, additional, Taira, Naoya, additional, Miyagi, Takashi, additional, Karimata, Kaori, additional, Ohama, Masayo, additional, Yamanoha, Atsushi, additional, Tamaki, Kazumitsu, additional, Hayashi, Masaki, additional, Uchihara, Jun-nosuke, additional, Ohshiro, Kazuiku, additional, Asakura, Yoshitaka, additional, Kuba-Miyara, Megumi, additional, Karube, Kennosuke, additional, Fukushima, Takuya, additional, and Masuzaki, Hiroaki, additional

Published
2017
Full Text
View/download PDF

16. Deletion of the TNFAIP3/A20gene detected by FICTION analysis in classical Hodgkin lymphoma

Author

Nomoto, Junko, primary, Hiramoto, Nobuhiro, additional, Kato, Motohiro, additional, Sanada, Masashi, additional, Maeshima, Akiko Miyagi, additional, Taniguchi, Hirokazu, additional, Hosoda, Fumie, additional, Asakura, Yoshitaka, additional, Munakata, Wataru, additional, Sekiguchi, Naohiro, additional, Maruyama, Dai, additional, Watanabe, Takashi, additional, Nakagama, Hitoshi, additional, Takeuchi, Kengo, additional, Tobinai, Kensei, additional, Ogawa, Seishi, additional, and Kobayashi, Yukio, additional

Published
2012
Full Text
View/download PDF

17. Engraftment Syndrome (ES) After Reduced-Intensity Stem Cell Transplantation (RIST): ES May Have a Negative Impact on Survival In Standard-Risk Patients

Author

Maeda, Takeshi, primary, Yakushijin, Kimikazu, additional, Asakura, Yoshitaka, additional, Hiramoto, Nobuhiro, additional, Kurosawa, Saiko, additional, Kamiyama, Yutaro, additional, Fukuhara, Suguru, additional, Ueno, Niina, additional, Kim, Sung-Won, additional, Mori, Shin-Ichiro, additional, Tanosaki, Ryuji, additional, Heike, Yuji, additional, Tobinai, Kensei, additional, Takaue, Yoichi, additional, and Fukuda, Takahiro, additional

Published
2010
Full Text
View/download PDF

18. Comparison of Outcomes After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) In 73 Patients with Follicular Lymphoma (FL), Transformed Follicular Lymphoma (TL), or De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Favorable Outcome for TL Similar to FL

Author

Tada, Kohei, primary, Kim, Sung-Won, additional, Asakura, Yoshitaka, additional, Hiramoto, Nobuhiro, additional, Yakushijin, Kimikazu, additional, Kurosawa, Saiko, additional, Ueno, Niina, additional, Kamiyama, Yutaro, additional, Fukuhara, Suguru, additional, Mori, Shinichiro, additional, Heike, Yuji, additional, Tanosaki, Ryuji, additional, Tobinai, Kensei, additional, Takaue, Yoichi, additional, and Fukuda, Takahiro, additional

Published
2010
Full Text
View/download PDF

20. Detection of Loss of A20 Gene by FICTION in Hodgkin's Lymphoma Cases.

Author

Nomoto, Junko, primary, Hiramoto, Nobuhiro, additional, Kato, Motohiro, additional, Sanada, Masashi, additional, Maeshima, Akiko, additional, Hosoda, Fumie, additional, Asakura, Yoshitaka, additional, Maruyama, Dai, additional, Watanabe, Takashi, additional, Tobinai, Kensei, additional, Nakagama, Hitoshi, additional, Ogawa, Seishi, additional, and Kobayashi, Yukio, additional

Published
2009
Full Text
View/download PDF

21. Long-Term Outcome of ATL Patients Who Underwent Reduced-Intensity Stem Cell Transplantation (RIST): Suggested Potent Graft-Versus-ATL and HTLV-1 Effects.

Author

Tanosaki, Ryuji, primary, Yakushijin, Kimikazu, additional, Asakura, Yoshitaka, additional, Kurosawa, Saiko, additional, Hiramoto, Nobuhiro, additional, Mori, Masakazu, additional, Fukuda, Takahiro, additional, Kim, Sung-Won, additional, Mori, Shin-ichiro, additional, Heike, Yuji, additional, Tobinai, Kensei, additional, and Takaue, Yoichi, additional

Published
2009
Full Text
View/download PDF

22. Aberrations of Genes Regulating NF Kappa B Pathway in B-Cell Malignant Lymphoma.

Author

Kato, Motohiro, primary, Sanada, Masashi, additional, Kato, Itaru, additional, Sato, Yasuharu, additional, Takita, Junko, additional, Kawahata, Ryoichiro, additional, Takeuchi, Kengo, additional, Niwa, Akira, additional, Chen, Yuyan, additional, Nakazaki, Kumi, additional, Nomoto, Junko, additional, Asakura, Yoshitaka, additional, Akatsuka, Yoshiki, additional, Hayashi, Yasuhide, additional, Igarashi, Takashi, additional, Kurokawa, Mineo, additional, Chiba, Shigeru, additional, Mori, Shigeo, additional, Ishikawa, Yuichi, additional, Okamoto, Koji, additional, Tobinai, Kensei, additional, Nakagama, Hitoshi, additional, Nakahata, Tatsutoshi, additional, Yoshino, Tadashi, additional, Kobayashi, Yukio, additional, and Ogawa, Seishi, additional

Published
2009
Full Text
View/download PDF

23. Renal Complications after Busulfan-Based Reduced-Intensity Stem Cell Transplantation in 286 Patients with Hematological Disorders.

Author

Yakushijin, Kimikazu, primary, Fukuda, Takahiro, additional, Asakura, Yoshitaka, additional, Kurosawa, Saiko, additional, Hiramoto, Nobuhiro, additional, Nakamura, Daisuke, additional, Tada, Kohei, additional, Nishinohara, Masaaki, additional, Hagiwara, Akihito, additional, Ueno, Niina, additional, Kamiyama, Yutaro, additional, Mori, Masakazu, additional, Kim, Sung-Won, additional, Mori, Shin-ichiro, additional, Tanosaki, Ryuji, additional, Heike, Yuji, additional, and Takaue, Yoichi, additional

Published
2009
Full Text
View/download PDF

24. Genome-Wide Analysis of B Cell Non-Hodgkin’s Lymphoma Disclosed Frequent Involvement of Genes in NFkB Pathway

Author

Kato, Motohiro, primary, Nakazaki, Kumi, additional, Sato, Yasuharu, additional, Takeuchi, Kengo, additional, Sanada, Masashi, additional, Asakura, Yoshitaka, additional, Muto, Satsuki, additional, Chen, Yuyan, additional, Takita, Junko, additional, Hayashi, Yasuhide, additional, Igarashi, Takashi, additional, Watanabe, Toshiki, additional, Tobinai, Kensei, additional, Ishikawa, Yuichi, additional, Mori, Shigeo, additional, Kurokawa, Mineo, additional, Yoshino, Tadashi, additional, Kobayashi, Yukio, additional, and Ogawa, Seishi, additional

Published
2008
Full Text
View/download PDF

26. Cytoreductive Regimen Containing Ranimustine (MCNU),Carboplatin, Etoposide and Cyclophosphamide (MCEC) Before Autologous Peripheral Blood Stem Cell Transplantation for Relapsed or Refractory Lymphoma

Author

Asakura, Yoshitaka, primary, Tanosaki, Ryuji, primary, Kim, Sung-Won, primary, Azuma, Teruhisa, primary, Kurosawa, Saiko, primary, Yakushijin, Kimikazu, primary, Maruyama, Dai, primary, Mori, Shin-ichiro, primary, Fukuda, Takahiro, primary, Watanabe, Takashi, primary, Kobayashi, Yukio, primary, Tobinai, Kensei, primary, and Takaue, Yoichi, primary

Published
2008
Full Text
View/download PDF

27. High Frequency of Loss of Heterozygosity Due to Uniparental Disomy or Allele Deletion of Ocular Adnexal MALT-Type Lymphoma.

Author

Asakura, Yoshitaka, primary, Ogawa, Seishi, primary, Kato, Motohiro, primary, Yamamoto, Go, primary, Maeshima, Akiko, primary, Matsuno, Yoshihiro, primary, Suzuki, Shigenobu, primary, Kaneko, Akihiro, primary, Nomoto, Junko, primary, Tanimoto, Kazuki, primary, Sekiguchi, Naohiro, primary, Maruyama, Dai, primary, Kim, Sung-Won, primary, Watanabe, Takashi, primary, Tobinai, Kensei, primary, and Kobayashi, Yukio, primary

Published
2007
Full Text
View/download PDF

29. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.

Author

Hashimoto, Kenji, Kobayashi, Yukio, Asakura, Yoshitaka, Mori, Masakazu, Azuma, Teruhisa, Maruyama, Dai, Kim, Sung-Won, Watanabe, Takashi, and Tobinai, Kensei

Subjects
PNEUMOCYSTIS pneumonia, B cells, HODGKIN'S disease, RITUXIMAB, CD4 antigen, DRUG therapy, LYMPHOCYTES
Abstract

An increasing incidence of Pneumocystis jiroveci pneumonia (PCP) in patients with B-cell non-Hodgkin lymphoma (B-NHL) receiving rituximab treatment has been reported. We reviewed patients with B-NHL who underwent chemotherapy from 2004 to 2008 at our institution to identify risk factors for PCP development during and after chemotherapy. Among 297 patients with B-NHL, six developed PCP. Of 121 patients (41%) who received PCP prophylaxis with sulfamethoxazole-trimethoprim during chemotherapy, none developed PCP (0%), while among 176 patients (59%) who had no prophylaxis, six (3.4%) developed PCP at a median of 2 months (range: 1-3 months) after starting chemotherapy. Patients with CD4+ lymphocyte counts ≤200/mm3 before chemotherapy had a higher risk of developing PCP ( p = 0.045), while a history of rituximab treatment was not related to PCP. CD4+ lymphocyte counts ≤200/mm3 during and after chemotherapy were observed in 18.9% of patients. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

30. Comparison of Outcomes After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) In 73 Patients with Follicular Lymphoma (FL), Transformed Follicular Lymphoma (TL), or De NovoDiffuse Large B-Cell Lymphoma (DLBCL): Favorable Outcome for TL Similar to FL

Author

Tada, Kohei, Kim, Sung-Won, Asakura, Yoshitaka, Hiramoto, Nobuhiro, Yakushijin, Kimikazu, Kurosawa, Saiko, Ueno, Niina, Kamiyama, Yutaro, Fukuhara, Suguru, Mori, Shinichiro, Heike, Yuji, Tanosaki, Ryuji, Tobinai, Kensei, Takaue, Yoichi, and Fukuda, Takahiro

Abstract

Abstract 3508

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results